Yazar "Tasci, I." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Correlations between transverse carpal ligament thickness measured on ultrasound and severity of carpal tunnel syndrome on electromyography and disease duration
    (Elsevier, 2022) Ari, B.; Akcicek, M.; Tasci, I.; Altunkilic, T.; Deniz, S.
    This study aimed to evaluate the relationship between transverse carpal ligament thickness on ultrasonography and disease severity according to electromyography findings. Fifty-eight patients with carpal tunnel syndrome, aged 30-75 years, with severe (Group 1) or moderate (Group 2) electromyography findings, who underwent surgery for carpal tunnel syndrome complaints in the previous 2 years were enrolled. Patient characteristics and clinical information were recorded. The patients completed the Boston carpal tunnel syndrome questionnaire and visual analog scale (VAS) pain score. Ultrasonography and electromyography records were examined. Electromyography showed that the median nerve area was similar in the two groups. Mean age, transverse carpal ligament thickness and symptom duration were greater in group 1, but not significantly. Mean VAS and Boston scores were significantly higher in group 1. Symptom duration did not affect median nerve area. Nerve area did not correlate significantly with VAS or Boston scores, transverse carpal ligament thickness or mean age, although averages were higher in patients with long symptom duration. Disease severity and symptom duration did not affect the ultrasonography findings. Disease severity in carpal tunnel syndrome could not be determined by measuring transverse carpal ligament thickness and median nerve area on ultrasonography without electromyography. (C) 2022 SFCM. Published by Elsevier Masson SAS. All rights reserved.
  • Küçük Resim Yok
    Öğe
    No association of anti-osteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort study
    (Springer London Ltd, 2022) Atmaca, A.; Demirci, I.; Haymana, C.; Tasci, I.; Sahin, I.; Cakal, E.; Ata, N.
    This study was performed to evaluate whether the use of drugs in the treatment of osteoporosis in women is associated with COVID-19 outcomes. The results showed that the risk of hospitalization, intensive care unit admission, and mortality was not altered in individuals taking anti-osteoporosis drugs, suggesting no safety issues during a COVID-19 infection. Introduction Whether patients with COVID-19 receiving anti-osteoporosis drugs have lower risk of worse outcomes has not been reported yet. The aim of this study was to evaluate the association of anti-osteoporosis drug use with COVID-19 outcomes in women. Methods Data obtained from a nationwide, multicenter, retrospective cohort of patients diagnosed with COVID-19 from March 11th to May 30th, 2020 was retrieved from the Turkish Ministry of Health Database. Women 50 years or older with confirmed COVID-19 who were receiving anti-osteoporosis drugs were compared with a 1:1 propensity score-matched COVID-19 positive women who were not receiving these drugs. The primary outcomes were hospitalization, ICU (intensive care unit) admission, and mortality. Results A total of 1997 women on anti-osteoporosis drugs and 1997 control patients were analyzed. In the treatment group, 1787 (89.5%) women were receiving bisphosphonates, 197 (9.9%) denosumab, and 17 (0.9%) teriparatide for the last 12 months. Hospitalization and mortality rates were similar between the treatment and control groups. ICU admission rate was lower in the treatment group (23.0% vs 27.0%, p = 0.013). However, multivariate analysis showed that anti-osteoporosis drug use was not an independent associate of any outcome. Hospitalization, ICU admission, and mortality rates were similar among bisphosphonate, denosumab, or teriparatide users. Conclusion Results of this nationwide study showed that preexisting use of anti-osteoporosis drugs in women did not alter the COVID-19-related risk of hospitalization, ICU admission, and mortality. These results do not suggest discontinuation of these drugs during a COVID-19 infection.